Porous 3D Silica Nanoparticle Assemblies as Post-surgical Drug Delivery Implants to Reduce Glioblastoma Recurrence
Porous 3D Silica Nanoparticle Assemblies as Post-surgical Drug Delivery Implants to Reduce Glioblastoma Recurrence
批准号:
EP/V009516/1
负责人:
Zhan Yuin Ong
金额:
$50.19万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2021
资助国家:
英国
项目状态:
已结题
起止时间:
2021 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Glioblastoma (GBM) is the most aggressive and common form of primary brain tumour in adults. GBM patients have an extremely poor median survival of < 15 months even with treatment. The occurrence of brain tumours is strongly related to age, and incidences worldwide and in the UK are rapidly rising; with a 39% rise in the UK since the 1990s to 12,071 new cases per year. The economic cost of brain tumours, including NHS treatment cost and loss of income, is ~£578 million per annum. Any technology that can improve the efficacy and safety of GBM treatment and patient outcomes will thus bear major cost savings for the UK economy. The treatment of GBM typically involves surgical tumour removal, radiotherapy, and chemotherapy. However, the aggressive tumour growth as finger-like tentacles in the brain often makes surgery ineffective, leading to unacceptably high tumour recurrence and mortality rates. As > 90% of tumour recurrences occur within 2 cm of the original tumour, the ability to prevent or delay local tumour regrowth after surgical removal of the bulk of the tumour mass will greatly improve patient outcomes. Indeed, the direct placement of a drug delivery device made from a drug-impregnated polymeric wafer (Glialdel) at the surgical site to kill residual cancer cells has modestly improved patient survival by 2 months. This approach also overcomes the usual challenge of drug delivery to the brain as it eliminates the need to transport the drug across the highly impermeable blood-brain barrier. However, the short acting nature of Glialdel has led to its small patient survival benefits, thus necessitating the development of more advanced drug delivery devices that could confer longer term drug release of more effective anticancer drugs to improve treatment outcomes.The aim of this project is to develop an implantable drug delivery technology to provide slow and sustained release of anticancer drugs in response to specific biological signals such as enzymes and chemicals after removal of the bulk of the tumour mass by neurosurgeons. This will be achieved by assembling 3D fibre-like structures from highly uniform porous silica nanoparticles. This system offers unprecedented porosity control for anticancer drugs to be loaded both inside the pores of the nanoparticles and in the spaces between the nanoparticles, thus enabling a high amount of anticancer drug to be delivered. As the pores between the nanoparticles are larger, faster initial drug release is expected, which will be followed by a slower sustained drug release from the smaller nanoparticle pores. The ability to precisely tune the interparticle pore sizes and surface area by varying the size and concentration of the nanoparticles and the inclusion of a natural polymer, hyaluronic acid, will allow the drug release to be more tightly regulated. This approach thus has the potential to provide steady long-term drug release which could improve the treatment safety and efficacy compared to other conventional local drug delivery systems. The 3D fibres will be formulated in a hydrogel to enhance their application at the brain cavity by neurosurgeons. The safety and efficacy of the 3D structures and hydrogel formulation will be studied in patient derived GBM and non-cancerous cells, which retain the native characteristics of the relevant human brain tissues.We have assembled a world-class multidisciplinary team of experts in materials chemistry, drug delivery, cancer biology, and neurosurgery to develop the drug delivery system. The complementary research expertise will ensure that the technology development is underpinned by a strong knowledge of cancer biology and clinical needs to maximise potential for technology translation and impact. The findings of this study will have wider applications for local drug delivery to other types of cancers and diseases for which the ability to control the release rates and provide long-term drug release is important.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.jcis.2022.02.052
发表时间:
2022-02
期刊:
Journal of colloid and interface science
影响因子:
9.9
作者:
[George Newham;S. Evans;Z. Ong]
通讯作者:
George Newham;S. Evans;Z. Ong
DOI:
10.1021/acsami.3c16463
发表时间:
2024-01-25
期刊:
ACS APPLIED MATERIALS & INTERFACES
影响因子:
9.5
作者:
[Palvai,Sandeep, Kpeglo,Delanyo, Ong,Zhan Yuin]
通讯作者:
Ong,Zhan Yuin
国内基金
海外基金
登录
查看更多内容
面向组织工程宏/微血管化的流道/多孔耦合生物 3D 打印研究
-
批准号:ZCLZ26C1001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:邵磊
-
依托单位:
高速喷气织机非标部件3D打印技术研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:陈雨莹
-
依托单位:
船舶海工用粘结剂喷射3D打印金属复合材料成形技术开发
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:徐龙
-
依托单位:
高效换热不锈钢模具3D打印关键技术及装备开发
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:刘双宇
-
依托单位:
3D打印纤维再生细骨料混凝土的研制和开发
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:李权
-
依托单位:
轨道角动量3D动态显示技术开发
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:林畅
-
依托单位:
柔性 3D 显示用圆偏振发光聚氨酯的无溶剂组装及手性放大机制
-
批准号:ZCLQN26B0401
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:段慧敏
-
依托单位:
适用于关节镜辅助单孔内镜脊柱融合手术的3D 打印融合器个性化设计及解剖适配效果研究
-
批准号:JCZRLH202600983
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
高活性肽-金属离子-骨水泥三重整合3D打印复合支架在糖尿病足创面修复中的作用机制研究
-
批准号:JCZRLH202600954
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
柑橘果胶基3D打印食用墨水构建及其负载辛弗林的控释机制
-
批准号:2026JJ60382
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:周鹏
-
依托单位: